Mucosis Overview

  • Founded
  • 2006
Founded
  • Status
  • Out of Business
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Liquidation

Mucosis General Information

Description

Developer of mucosal vaccines designed to treat infectious diseases. The company's mucosal vaccines are based on the Mimopath technology which can be applied needle-free via the nose or mouth, addressing the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune system to fight against diseases such as RSV, pneumococci and influenza.

Contact Information

Website
www.mucosis.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Meditech Center
  • L.J. Zielstraweg 1
  • 9713 GX Groningen
  • Netherlands
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mucosis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Bankruptcy: Liquidation 27-Jun-2017 000.00 Completed Bankruptcy: Liquidation
8. Grant 20-Jan-2016 00.000 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC 20-Jan-2016 00.000 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series C) 16-Jan-2015 00.00 000.00 Completed Clinical Trials - Phase 1
5. Debt - General 22-May-2014 00.00 000.00 Completed Clinical Trials - Phase 1
4. Later Stage VC 29-Apr-2014 00.00 000.00 Completed Clinical Trials - Phase 1
3. Grant 25-Sep-2012 00.000 00.000 Completed Clinical Trials - Phase 1
2. Debt - General 31-May-2010 $3.76M $7.85M Completed Startup
1. Early Stage VC (Series A) 10-Sep-2007 $4.09M $4.09M Completed Startup
To view Mucosis’s complete valuation and funding history, request access »

Mucosis Executive Team (7)

Name Title Board Seat Contact Info
Thomas Johnston Office Manager & Chief Executive Officer
Maarten van Roosmalen Ph.D Director, Research & Development & Co-Founder
Jolande Schoemaker Quality Assurance Director
Roberto Grimaldi MD Chief Medical Officer
You’re viewing 4 of 7 executive team members. Get the full list »

Mucosis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial